# US 8,709,445 B2 · Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,709,445 B2
- Document ID: US8709445B2
- Status: Granted
- Kind: B2
- Application number: 12/671,184
- Filed: 2008-07-31
- Published: 2010-12-09
- Granted: 2014-04-29
- Earliest claimed: 2007-07-31
- Assignees: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
- Applicants: Noah A. Craft; Kevin W. Bruhn; Ron A. Birnbaum
- Inventors: Noah A. Craft; Kevin W. Bruhn; Ron A. Birnbaum
- Web page: https://patentgrep.com/patent/US8709445B2

## CPC

- A61K 39/008: Leishmania antigens
- A61K 39/002: Protozoa antigens
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/55511: {Organic adjuvants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.

## Claims

### Claim 1

A composition for inducing an immune response in a vertebrate host against a protozoan parasite, said composition comprising:
a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA);
wherein said composition is formulated for administration to a vertebrate; and
when administered to a vertebrate induces an immune response in said vertebrate where said immune response is directed against the protozoan parasite.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said protozoan parasite comprises a DNA modified with a psoralen selected from the group consisting of psoralen, isopsoralen, TMP, HMT, 8-MOP, AMT, and S-59.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said composition further comprises an adjuvant.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said adjuvant comprises a toll-like receptor agonist.

### Claim 5 (depends on 3)

The composition of claim 3, wherein said adjuvant comprises an agonist for TLR-7 and/or TLR-8.

### Claim 6 (depends on 3)

The composition of claim 3, wherein said toll-like receptor agonist comprises an imidazoquinolinamine.

### Claim 7 (depends on 3)

The composition of claim 3, wherein said toll-like receptor agonist comprises a nucleoside analogue.

### Claim 8 (depends on 3)

The composition of claim 3, wherein said toll-like receptor agonist comprises one or more agents selected from the group consisting of imiquimod, resiquimod (R-848), 3M-001, 3M-002, flagellin, poly U, Loxoribine, and CPG-A DNA, CpG-C DNA, 7-thia-8-oxoguanosinyl, 7-deazaguanosinyl, and abrogate.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the protozoan parasite belongs to the phylum Apicomplexa, or Kinetoplastida.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the protozoan parasite belongs to a genus selected from the group consisting of Plasmodium, Toxoplasma, Neospora, Eimeria, Theileria, Babesia, Cryptosporidium, Sarcocystis, and Leucocytozoon, Leishmania, and Trypansoma.

### Claim 11 (depends on 1)

The composition of claim 1, wherein said composition is formulated for administration by a method selected from the group consisting of topical administration, subcutaneous administration, intramuscular administration, intravenous administration, transdermal administration, inhalation administration, and oral administration.

### Claim 12 (depends on 1)

The composition of claim 1, wherein said composition is formulated for administration to a vertebrate selected from the group consisting of bird, canine, equine, feline, porcine, bovine, human, and non-human primate.
